Carlos Lorena
Bioavailability is a critical factor in the efficacy of Active Pharmaceutical Ingredients (APIs). Two key physical properties influencing bioavailability are polymorphism and particle size. Polymorphism refers to the ability of a compound to exist in more than one crystalline form, while particle size impacts the dissolution rate and, consequently, the bioavailability of the API. This article explores the mechanisms by which polymorphism and particle size affect bioavailability, supported by recent research and case studies.
Maria Faramarzi
Liposomal formulations represent a significant advancement in drug delivery systems, offering enhanced bioavailability and targeted delivery. This research article reviews recent advancements in liposomal technology, focusing on strategies to improve bioavailability, targeting specificity and therapeutic efficacy. The discussion encompasses innovations in liposomal design, surface modifications and novel applications in medicine.
Richard Saraiva
Biologics, encompassing a wide range of therapeutic products derived from biological sources, have become integral to modern medicine. However, their complex nature poses significant challenges in terms of stability and bioavailability. This article explores various formulation strategies employed to address these challenges, highlighting recent advancements and their implications for the pharmaceutical industry.
Brigitta Steven
Microneedle technologies represent a transformative approach in transdermal drug delivery, offering significant improvements in bioavailability and patient compliance. This article reviews the latest advancements in microneedle technology, including its mechanisms, types, applications and future perspectives. The potential benefits of microneedles in enhancing drug absorption, minimizing pain and simplifying administration are discussed, along with challenges and opportunities for further research.